Drug intelligence / Profile preview

Trimabion

Development stage: Unknown
Lead developer: Triman
Modality: Small Molecules
Administration: Oral

Overview

Trimabion is a nutritional supplement developed and manufactured by the Indonesian pharmaceutical company Triman. It is formulated as a combination of neurotropic vitamins, specifically vitamin B1 (thiamine), vitamin B6 (pyridoxine), and vitamin B12 (cobalamin). These vitamins are essential for maintaining the structural and functional integrity of the nervous system: vitamin B1 is involved in carbohydrate metabolism and nerve fiber maintenance; vitamin B6 acts as a cofactor in protein metabolism and the synthesis of neurotransmitters; and vitamin B12 is critical for cell maturation and the maintenance of the myelin sheath. Trimabion is primarily indicated for nutritional supplementation and the support of nerve health.

Brand names: Trimabion
Other names: vitamin B1 + vitamin B6 + vitamin B12

Beyond the preview

Go deeper on Trimabion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trimabion.

Explore the full profile